mProX™ Human TNFRSF17 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;A549;SPC-A1

Target Classification

Oncology Cell Lines

Target Research Area

Cancer Research

Related Diseases

Lymphoma; Macroglobulinemia

Gene ID

Human:608

UniProt ID

Human:Q02223

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF17, also known as B cell maturation antigen (BCMA), is a target for immunotherapies in multiple myeloma (MM). However, antigen escape from BCMA-targeted therapies can occur, leading to resistance. This study investigated the mechanisms of antigen escape in MM patients treated with BCMA or GPRC5D-targeted immunotherapies. The researchers performed whole-genome sequencing and copy number variation analysis on patient samples and identified various mechanisms of antigen escape, including BCMA-negative clones with TNFRSF17 deletions and BCMA mutations that rendered anti-BCMA therapies ineffective. They also found cases of GPRC5D mutations after anti-GPRC5D therapy. The study highlights the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM. Another study focused on oral squamous cell carcinoma (OSCC) and used bioinformatics analysis to identify potential molecular mechanisms and prognostic markers. The researchers analyzed gene expression datasets and identified differentially expressed genes (DEGs) associated with OSCC. They found that TNFRSF17, along with other genes, was a hub gene and a favorable prognostic marker for OSCC. The study suggests that TNFRSF17 could be used as a potential therapeutic target and tumor marker in OSCC. Additionally, a study investigated the influences of COVID-19 co-infection with influenza virus on chronic obstructive pulmonary disease (COPD). The researchers used bioinformatics and systems biology approaches to identify DEGs associated with COVID-19, influenza virus A, and COPD. TNFRSF17 was among the top hub genes identified, suggesting its potential role in the co-infection. The study also identified several drugs that could potentially treat the co-infection. Lastly, a study examined the serum levels and significance of soluble BCMA in childhood-onset systemic lupus erythematosus (cSLE) with renal involvement. The researchers found that serum BCMA levels were significantly increased in cSLE patients compared to healthy controls. They also observed a positive correlation between serum BCMA levels and disease activity in cSLE patients. The study suggests that serum BCMA could serve as a biomarker in cSLE patients. Overall, these studies highlight the diverse applications of TNFRSF17 in different diseases and provide insights into its role in immunotherapies, prognostic markers, and disease mechanisms.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TNFRSF17 Stable Cell Line (S01YF-1023-PY236). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Johnson (Verified Customer)

What is the role of TNFRSF17 in multiple myeloma? Aug 07 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF17, also known as BCMA, is implicated in the resistance to targeted immunotherapies in multiple myeloma, suggesting its significance in disease progression and treatment response. Aug 07 2021

chat Skyler Brown (Verified Customer)

Can TNFRSF17 be used as a prognostic marker in colon cancer? Aug 15 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF17, along with MS4A1, can serve as markers to predict the sensitivity of patients with colon cancer to immunotherapy and potentially inhibit cancer progression. Aug 15 2020

Published Data

Fig.1 Knockdown of TNFRSF17 in A549 and SPC-A1 cells.

A549 and SPC-A1 cells were transfected with the small interfering RNAs against TNFRSF17and the protein expression of TNFRSF17 was determined by western blot analysis.

Ref: Lin, Yanliang, et al. "25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis." (2023).

Pubmed: NA

DOI: NA

Research Highlights

Lee, Holly. et al. "Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma." Nature medicine, 2023.
Recent research has shown that B cell maturation antigen (BCMA) target loss is a rare occurrence in multiple myeloma (MM). However, it has been found to be a key factor in resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. A study was conducted on 30 patients treated with these therapies to identify tumor-intrinsic factors that contribute to MM antigen escape. It was discovered that BCMA-negative and GPRC5D mutations were responsible for relapse in some cases, highlighting the need to consider the tumor antigen landscape when designing targeted treatments for MM.
Lee, Holly. et al. "Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma." Nature medicine, 2023.
Pubmed: 37653344 DOI: 10.1038/s41591-023-02491-5

Chujan, Suthipong. et al. "Identification of Potential Molecular Mechanisms and Prognostic Markers for Oral Squamous Cell Carcinoma: A Bioinformatics Analysis." Journal of International Society of Preventive & Community Dentistry, 2023.
The aim of the present study was to identify critical biochemical pathways, prognostic indicators, and therapeutic targets in individuals diagnosed with oral cancer, with the ultimate goal of improving treatment approaches.
Chujan, Suthipong. et al. "Identification of Potential Molecular Mechanisms and Prognostic Markers for Oral Squamous Cell Carcinoma: A Bioinformatics Analysis." Journal of International Society of Preventive & Community Dentistry, 2023.
Pubmed: 37564170 DOI: 10.4103/jispcd.JISPCD_15_23